Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 27, 2018 08:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2017 Financial Results

SAN DIEGO, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for...
February 23, 2018 08:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Receipt of CIRM Grant for Clinical Translation of FT516 Off-the-Shelf Engineered NK Cell Cancer Immunotherapy

SAN DIEGO, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for...
February 20, 2018 08:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces First Subject Treated with FATE-NK100 in DIMENSION Study for Advanced Solid Tumors

SAN DIEGO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for...
February 12, 2018 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Present at the Leerink Partners 7th Annual Global Healthcare Conference

SAN DIEGO, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies...
December 15, 2017 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, Dec. 15, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for...
December 13, 2017 08:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Pricing of Public Offering of Common Stock

SAN DIEGO, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for...
December 12, 2017 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Proposed Public Offering of Common Stock

SAN DIEGO, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for...
December 11, 2017 18:13 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Day 100 Clinical Results from Phase 1 Stage of PROTECT Trial of ProTmune™ and Initiation of Phase 2 Stage

All Subjects Achieved Day 100 Relapse-free Survival All Incidents of Day 100 Acute GvHD Responded to Steroid Treatment Randomized, Controlled and Double-Blinded Phase 2 Stage of PROTECT Now...
December 11, 2017 16:30 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Successful Completion of Technology Transfer and Initiation of IND-Enabling Manufacture of FT500

SAN DIEGO, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular...
December 09, 2017 12:30 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Generation of CAR-targeted, TCR-null CD8αβ+ T Cells from Clonal Engineered Master Pluripotent Cell Line for Off-the-Shelf T-cell Immunotherapy

One-time Engineering Event Using iPSCs and CRISPR/Cas9 Yields Genetically Modified, Self-Renewing Clonal Master Pluripotent Cell Line Master Pluripotent Cell Line Engineered with Complete Elimination...